Free Trial

Aytu BioPharma (AYTU) Competitors

Aytu BioPharma logo
$2.63 -0.02 (-0.75%)
Closing price 04:00 PM Eastern
Extended Trading
$2.58 -0.05 (-2.05%)
As of 07:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AYTU vs. VRCA, ADAP, MIST, SRZN, PYXS, ANRO, JMAC, BMEA, VNRX, and INCR

Should you be buying Aytu BioPharma stock or one of its competitors? The main competitors of Aytu BioPharma include Verrica Pharmaceuticals (VRCA), Adaptimmune Therapeutics (ADAP), Milestone Pharmaceuticals (MIST), Surrozen (SRZN), Pyxis Oncology (PYXS), Alto Neuroscience (ANRO), Maxpro Capital Acquisition (JMAC), Biomea Fusion (BMEA), VolitionRx (VNRX), and InterCure (INCR). These companies are all part of the "pharmaceutical products" industry.

Aytu BioPharma vs. Its Competitors

Aytu BioPharma (NASDAQ:AYTU) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

Aytu BioPharma presently has a consensus price target of $10.00, suggesting a potential upside of 280.23%. Verrica Pharmaceuticals has a consensus price target of $8.00, suggesting a potential upside of 21.03%. Given Aytu BioPharma's stronger consensus rating and higher probable upside, research analysts clearly believe Aytu BioPharma is more favorable than Verrica Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aytu BioPharma
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Verrica Pharmaceuticals
0 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.20

33.5% of Aytu BioPharma shares are owned by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. 3.6% of Aytu BioPharma shares are owned by company insiders. Comparatively, 54.0% of Verrica Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Aytu BioPharma has a beta of 0.13, suggesting that its stock price is 87% less volatile than the S&P 500. Comparatively, Verrica Pharmaceuticals has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500.

In the previous week, Aytu BioPharma and Aytu BioPharma both had 2 articles in the media. Verrica Pharmaceuticals' average media sentiment score of 1.87 beat Aytu BioPharma's score of 0.94 indicating that Verrica Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aytu BioPharma
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Verrica Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Aytu BioPharma has a net margin of 2.37% compared to Verrica Pharmaceuticals' net margin of 0.00%. Aytu BioPharma's return on equity of 3.51% beat Verrica Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Aytu BioPharma2.37% 3.51% 0.91%
Verrica Pharmaceuticals N/A N/A -145.63%

Aytu BioPharma has higher revenue and earnings than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aytu BioPharma$81.66M0.29-$15.84M-$0.72-3.65
Verrica Pharmaceuticals$7.18M85.16-$76.58M-$1.20-5.51

Summary

Aytu BioPharma beats Verrica Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

Get Aytu BioPharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for AYTU and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AYTU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AYTU vs. The Competition

MetricAytu BioPharmaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$23.61M$3.04B$5.74B$9.51B
Dividend YieldN/A2.40%4.60%3.99%
P/E Ratio-3.6521.1828.1120.03
Price / Sales0.29339.43461.37103.88
Price / CashN/A43.2336.5559.01
Price / Book0.578.368.655.90
Net Income-$15.84M-$55.19M$3.25B$258.66M
7 Day Performance10.97%5.89%4.20%2.23%
1 Month Performance22.33%17.63%10.82%12.76%
1 Year Performance-2.59%5.09%34.70%19.36%

Aytu BioPharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AYTU
Aytu BioPharma
4.135 of 5 stars
$2.63
-0.8%
$10.00
+280.2%
-3.6%$23.61M$81.66M-3.65160
VRCA
Verrica Pharmaceuticals
4.1329 of 5 stars
$0.82
+1.0%
$8.00
+881.6%
-90.2%$75.38M$7.57M-0.6840Positive News
Gap Down
ADAP
Adaptimmune Therapeutics
1.9629 of 5 stars
$0.28
+4.6%
$1.35
+381.0%
-73.0%$74.48M$178.03M-1.04490News Coverage
MIST
Milestone Pharmaceuticals
2.8103 of 5 stars
$1.38
-11.5%
$7.00
+407.2%
+6.1%$73.78M$1M-1.7730High Trading Volume
SRZN
Surrozen
2.7641 of 5 stars
$8.61
-1.1%
$38.50
+347.2%
+5.3%$73.73M$11.64M-0.3480Positive News
PYXS
Pyxis Oncology
2.4157 of 5 stars
$1.19
+2.6%
$9.00
+656.3%
-64.5%$73.72MN/A-0.7560
ANRO
Alto Neuroscience
2.4036 of 5 stars
$2.71
+4.0%
$8.50
+214.2%
-79.4%$73.22MN/A-1.16N/ATrending News
JMAC
Maxpro Capital Acquisition
N/A$5.45
-4.4%
N/A+2,812.2%$73.18MN/A0.002,021Gap Up
BMEA
Biomea Fusion
3.2899 of 5 stars
$1.94
-3.0%
$21.40
+1,003.1%
-66.8%$72.89MN/A-0.5550Upcoming Earnings
VNRX
VolitionRx
1.5738 of 5 stars
$0.68
+2.5%
$3.50
+411.2%
-1.9%$71.20M$1.31M-1.9080
INCR
InterCure
0.6636 of 5 stars
$1.55
flat
N/A-34.5%$70.63M$238.85M0.00350Positive News

Related Companies and Tools


This page (NASDAQ:AYTU) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners